financetom
Business
financetom
/
Business
/
Samsung wins interim licence in UK patent fight with ZTE
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Samsung wins interim licence in UK patent fight with ZTE
Jun 25, 2025 7:38 AM

LONDON (Reuters) -Samsung Electronics on Wednesday won a ruling from London's High Court in its attempt to get an interim licence to use ZTE's patents, in the English leg of the firms' global licensing dispute over mobile phone patents.

English courts have recently permitted parties to pursue short-term patent licences pending trial, including in Amazon's dispute with Nokia and Lenovo's battle with Ericsson, before both ultimately settled.

Wednesday's ruling, though, is the first time in England that a court of first instance - the initial court where a case is heard - has made such an interim licence declaration.

Disputes over the fair, reasonable, and non-discriminatory (FRAND) terms of a patent licence have frequently led to global legal battles in the telecom industry.

English courts can set global FRAND terms, following a landmark 2020 UK Supreme Court ruling, as can courts in China.

Samsung sued ZTE in London in December 2024 seeking a determination of FRAND terms, with ZTE bringing parallel lawsuits against Samsung in China, Germany and Brazil.

In London, Samsung sought a declaration that a willing licensor in ZTE's position would agree to an interim licence until FRAND terms were decided by the court.

Both Samsung and ZTE had made competing offers for an interim licence, with ZTE's licence requiring FRAND terms to be those determined by a court in China.

London's High Court ruled in Samsung's favour on Wednesday, with Judge James Mellor saying that "ZTE have acted in bad faith with their wave of unnecessary injunctive proceedings".

The judge added that "ZTE's terms are designed to render this action (in London) pointless, so that Samsung effectively has to abandon it" in favour of accepting the outcome of ZTE's lawsuit in Chongqing in southwestern China.

Samsung and ZTE did not immediately respond to a request for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Evercore to acquire British boutique investment bank Robey Warshaw for $196 million
Evercore to acquire British boutique investment bank Robey Warshaw for $196 million
Aug 21, 2025
July 30 (Reuters) - Evercore ( EVR ) will acquire British boutique investment bank Robey Warshaw for $196 million, the U.S. investment bank said on Wednesday. Payment will be made in two tranches, half in Evercore ( EVR ) shares when the deal closes and the remainder a year later in either cash or stock, Evercore's ( EVR ) statement...
Bowman Selected for IDOT US 30 Preliminary Engineering in Illinois
Bowman Selected for IDOT US 30 Preliminary Engineering in Illinois
Aug 21, 2025
08:03 AM EDT, 08/21/2025 (MT Newswires) -- Bowman Consulting Group ( BWMN ) said Thursday it was chosen by the Illinois Department of Transportation to deliver preliminary engineering, including an environmental impact statement, for US 30 improvements in Morrison. Phase 1 covers reconstruction along portions of the historic Lincoln Highway and will include an EIS following public and stakeholder involvement...
Mediobanca shareholders reject Banca Generali deal in blow to takeover defence
Mediobanca shareholders reject Banca Generali deal in blow to takeover defence
Aug 21, 2025
MILAN (Reuters) -Mediobanca shareholders on Thursday rejected a plan to buy Banca Generali, dealing a blow to the Italian merchant bank's attempts to thwart a hostile takeover by Monte dei Paschi di Siena (MPS). The bid battles are among a series of transactions which have been reshaping Italy's banking landscape as companies look for scale. Mediobanca had pitched the Banca...
Evoke Pharma Says US FDA Lists Latest US Patent for Gimoti Nasal Spray in Orange Book
Evoke Pharma Says US FDA Lists Latest US Patent for Gimoti Nasal Spray in Orange Book
Aug 21, 2025
08:09 AM EDT, 08/21/2025 (MT Newswires) -- Evoke Pharma ( EVOK ) said Thursday its US patent related to the use of Gimoti nasal spray for patients with gastroparesis is now listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or 'Orange Book.' The newly listed patent is anticipated to expire Nov. 17, 2038,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved